Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://ncbi.nlm.nih.gov/pubmed/30818873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030283
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi